Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 451,767 | 354,264 | 325,719 | 264,861 | 298,008 |
| Cost of Goods | 78,770 | 55,242 | 46,359 | 48,403 | 42,055 |
| Gross Profit | 372,997 | 299,022 | 279,360 | 216,458 | 255,953 |
| Operating Expenses | 466,658 | 81,343 | 77,278 | 75,326 | 80,507 |
| Operating Income | -92,891 | 217,921 | 202,441 | 141,535 | 175,501 |
| Interest Expense | 4,911 | 4,296 | 4,394 | 4,525 | 4,540 |
| Other Income | -3,047 | 5,333 | 6,891 | 6,818 | 7,253 |
| Pre-tax Income | -100,849 | 218,958 | 204,938 | 143,828 | 178,214 |
| Income Tax | 40,742 | 43,733 | 39,778 | 25,733 | 41,202 |
| Net Income Continuous | -141,591 | 175,225 | 165,160 | 118,095 | 137,012 |
| Net Income | $-141,591 | $175,225 | $165,160 | $118,095 | $137,012 |
| EPS Basic Total Ops | -1.17 | 1.49 | 1.36 | 0.96 | 1.08 |
| EPS Basic Continuous Ops | -1.17 | 1.49 | 1.36 | 0.96 | 1.08 |
| EPS Diluted Total Ops | -1.13 | 1.43 | 1.33 | 0.93 | 1.06 |
| EPS Diluted Continuous Ops | -1.14 | 1.43 | 1.33 | 0.93 | 1.06 |
| EPS Diluted Before Non-Recurring Items | -0.35 | 1.63 | 1.47 | 1.03 | 1.19 |
| EBITDA(a) | $-64,357 | $239,842 | $223,661 | $162,121 | $195,362 |